Catalent, Inc. (NYSE:CTLT) Given Average Rating of “Hold” by Analysts

Shares of Catalent, Inc. (NYSE:CTLT) have been given an average recommendation of “Hold” by the seven analysts that are currently covering the stock, MarketBeat.com reports. Seven research analysts have rated the stock with a hold rating. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $63.40.

A number of research firms have recently commented on CTLT. StockNews.com initiated coverage on Catalent in a report on Monday. They issued a “hold” rating on the stock. Robert W. Baird reissued a “neutral” rating and set a $63.50 price objective on shares of Catalent in a report on Tuesday, September 24th. Finally, Baird R W downgraded Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th.

Catalent Price Performance

Shares of NYSE:CTLT opened at $63.48 on Tuesday. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38. Catalent has a fifty-two week low of $41.15 and a fifty-two week high of $63.50. The stock has a market cap of $11.52 billion, a price-to-earnings ratio of -28.09, a price-to-earnings-growth ratio of 2.69 and a beta of 1.15. The firm’s 50 day moving average price is $62.24 and its 200 day moving average price is $60.47.

Catalent (NYSE:CTLT) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.06 billion. Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. Catalent’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.10) earnings per share. As a group, equities research analysts predict that Catalent will post 0.78 earnings per share for the current fiscal year.

Insider Activity at Catalent

In other Catalent news, Director Michelle R. Ryan sold 2,800 shares of the business’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $59.70, for a total transaction of $167,160.00. Following the sale, the director now directly owns 10,835 shares in the company, valued at approximately $646,849.50. The trade was a 20.54 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.31% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in CTLT. Brooklyn Investment Group purchased a new stake in Catalent during the third quarter worth $31,000. Sentry Investment Management LLC purchased a new stake in shares of Catalent in the 3rd quarter worth about $53,000. Thurston Springer Miller Herd & Titak Inc. grew its stake in Catalent by 57.5% in the 3rd quarter. Thurston Springer Miller Herd & Titak Inc. now owns 1,181 shares of the company’s stock valued at $72,000 after acquiring an additional 431 shares during the last quarter. Intact Investment Management Inc. acquired a new position in shares of Catalent during the 3rd quarter worth approximately $73,000. Finally, GAMMA Investing LLC lifted its position in shares of Catalent by 26.9% in the third quarter. GAMMA Investing LLC now owns 1,310 shares of the company’s stock valued at $79,000 after acquiring an additional 278 shares in the last quarter.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.